NCT04917692View on ClinicalTrials.gov

Empagliflozin in Adolescent Diabetes

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

July 31, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

October 31, 2022

Conditions

type1diabetes

Interventions

DRUG

Empagliflozin

2.5 mg daily

Trial Locations (1)

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Diacomp

UNKNOWN

lead

Ohio State University

OTHER